Bio­con’s in­sulin biosim­i­lar re­ject­ed yet again by FDA af­ter man­u­fac­tur­ing de­fi­cien­cies

The FDA has re­ject­ed Bio­con Bi­o­log­ics’ biosim­i­lar ver­sion of in­sulin as­part due to is­sues iden­ti­fied at its Malaysia fa­cil­i­ty af­ter an Aug. 2022 in­spec­tion. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER